Literature DB >> 16360021

Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells.

Sonja Offner1, Robert Hofmeister, Andrea Romaniuk, Peter Kufer, Patrick A Baeuerle.   

Abstract

Certain bispecific single-chain antibody constructs exhibit an extraordinary potency for polyclonal T cell engagement and target cell lysis. Here we studied the structural basis for this potency, using laser scanning confocal microscopy. Cytolytic human T cell synapses could be triggered either by addition of a specific peptide antigen or an Ep-CAM-/CD3-bispecific T cell engager (BiTE). Both kinds of synapses showed a comparable distribution of all protein markers investigated. Two other BiTEs constructed from different Ep-CAM-specific antibodies gave similar results. BiTEs could also induce lytic synapses between human T cells and a MHC class I-negative, Ep-CAM cDNA-transfected cell line resulting in potent target cell lysis. This shows that certain T cell recognition molecules on target cells are dispensable for synapse formation and BiTE activity, and suggests that BiTE-activated polyclonal T cells may ignore major immune evasion mechanisms of tumor cells in vivo, such as loss of MHC class I expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16360021     DOI: 10.1016/j.molimm.2005.03.007

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  118 in total

Review 1.  Bispecific T-cell engagers for cancer immunotherapy.

Authors:  Amelia M Huehls; Tiffany A Coupet; Charles L Sentman
Journal:  Immunol Cell Biol       Date:  2014-11-04       Impact factor: 5.126

2.  World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA.

Authors:  Eugen Dhimolea; Janice M Reichert
Journal:  MAbs       Date:  2012 Jan-Feb       Impact factor: 5.857

3.  Synthesis of bispecific antibodies using genetically encoded unnatural amino acids.

Authors:  Chan Hyuk Kim; Jun Y Axup; Anna Dubrovska; Stephanie A Kazane; Benjamin A Hutchins; Erik D Wold; Vaughn V Smider; Peter G Schultz
Journal:  J Am Chem Soc       Date:  2012-06-06       Impact factor: 15.419

4.  A BiTE from cancer's intracellular menu.

Authors:  Alexander I Salter; Stanley R Riddell
Journal:  Nat Biotechnol       Date:  2015-10       Impact factor: 54.908

5.  Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site.

Authors:  Thomas List; Dario Neri
Journal:  MAbs       Date:  2012-10-02       Impact factor: 5.857

6.  Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.

Authors:  Sahra Ali; Alexandre Moreau; Daniela Melchiorri; Jorge Camarero; Filip Josephson; Odoardo Olimpier; Jonas Bergh; Dominik Karres; Kyriaki Tzogani; Christian Gisselbrecht; Francesco Pignatti
Journal:  Oncologist       Date:  2019-11-14

7.  B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity.

Authors:  Ming-Ru Wu; Tong Zhang; Albert T Gacerez; Tiffany A Coupet; Leslie R DeMars; Charles L Sentman
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

Review 8.  T cell-engaging therapies - BiTEs and beyond.

Authors:  Maria-Elisabeth Goebeler; Ralf C Bargou
Journal:  Nat Rev Clin Oncol       Date:  2020-04-02       Impact factor: 66.675

9.  Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.

Authors:  Bryan D Choi; Chien-Tsun Kuan; Mingqing Cai; Gary E Archer; Duane A Mitchell; Patrick C Gedeon; Luis Sanchez-Perez; Ira Pastan; Darell D Bigner; John H Sampson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

Review 10.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.